HC Wainwright Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its price target raised by HC Wainwright from $30.00 to $35.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 59.67% from the company’s current price.

A number of other analysts have also issued reports on CPRX. Bank of America reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 3rd. Finally, Stephens initiated coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.86.

Catalyst Pharmaceuticals Trading Down 3.9 %

NASDAQ:CPRX opened at $21.92 on Friday. The firm has a market capitalization of $2.61 billion, a PE ratio of 18.58, a PEG ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals has a 1 year low of $13.12 and a 1 year high of $24.27. The firm’s fifty day simple moving average is $21.77 and its 200 day simple moving average is $19.98.

Insider Activity

In other news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. The trade was a 18.93 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,500 shares of company stock worth $1,754,140. Company insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Pacer Advisors Inc. lifted its position in Catalyst Pharmaceuticals by 130,918.8% during the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after buying an additional 2,965,310 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after buying an additional 287,300 shares in the last quarter. Jane Street Group LLC boosted its position in Catalyst Pharmaceuticals by 245.4% in the 3rd quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after buying an additional 285,564 shares during the last quarter. Integral Health Asset Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at $4,260,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after acquiring an additional 263,099 shares during the period. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.